Mesopancreas Excision in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma
A legfontosabb adatok
- Ki végzi
- Minia University
- Hol
- Egyiptom1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 110 fő, tervezett
- Kezdés
- 2026. nov. 25.
- Várható befejezés
- 2029. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Pancreaticoduodenectomy with total mesopancreas excision
- Standard pancreaticoduodenectomy
- A regiszteradat frissítve
- 2026. november 18.
Ki vehet részt
- Életkor
- 18 év – 75 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Age 18 to 75 years
- Solid tumor of the pancreatic head or uncinate process with a cytological or histological diagnosis of pancreatic ductal adenocarcinoma or, when a tissue diagnosis is not available, imaging features typical of pancreatic ductal adenocarcinoma accepted by the multidisciplinary tumor board
- Resectable disease according to NCCN criteria on pancreatic-protocol contrast-enhanced CT performed within 4 weeks before surgery: no arterial tumor contact (celiac axis, superior mesenteric artery or common hepatic artery), and no contact with the superior mesenteric vein or portal vein or contact of 180 degrees or less without vein contour irregularity
- Planned upfront open pancreaticoduodenectomy with curative intent
- ECOG performance status 0 or 1
- American Society of Anesthesiologists (ASA) physical status I to III
- Written informed consent, including consent to randomization during surgery
- Confirmation at laparotomy, before randomization, of no peritoneal or liver metastases and no tumor involvement of the superior mesenteric artery, celiac axis or common hepatic artery
Ki nem vehet részt
- Previous chemotherapy, chemoradiotherapy or radiotherapy for the current tumor
- Planned total pancreatectomy or arterial resection
- Previous pancreatic resection, or previous major surgery around the superior mesenteric vessels or in the retroperitoneum near the pancreas
- Borderline resectable or locally advanced disease, or distant metastases, on preoperative staging
- Liver cirrhosis of Child-Pugh class B or C, or portal hypertension
- Other active malignancy, or previous malignancy within 5 years other than non-melanoma skin cancer or carcinoma in situ of the cervix
- Emergency surgery for bleeding or perforation
- Preoperative diagnosis of another tumor type, including ampullary, distal bile duct or duodenal carcinoma, neuroendocrine neoplasm, acinar cell carcinoma, solid pseudopapillary neoplasm or lymphoma
- Planned laparoscopic or robotic pancreaticoduodenectomy
- Pregnancy or breastfeeding
- Inability to attend follow-up or to give informed consent
- Participation in another interventional trial that could affect the study outcomes
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is treated when it arises in the head of the pancreas and can be removed by an operation called pancreaticoduodenectomy (the Whipple operation), followed by chemotherapy. Even after this operation the cancer returns in most patients. One important reason is that microscopic cancer cells are often left at the cut edges of the removed tissue, especially at the edge facing the superior mesenteric artery, the main artery that supplies the intestine. The tissue in this area, behind the head of the pancreas, is called the mesopancreas. It contains fat, lymph vessels, lymph nodes and nerves, through which pancreatic cancer commonly spreads.
A teljes eredeti leírásKevesebb
Total mesopancreas excision is a refinement of the standard operation. The surgeon removes the whole mesopancreas in one piece together with the head of the pancreas by dissecting directly along the right side of the superior mesenteric artery, in the same way that the whole fatty envelope of the rectum is removed in rectal cancer surgery. Studies that compared patients operated on with and without this technique suggest that it may leave fewer cancer cells behind and reduce the chance of the cancer returning in the operated area, without increasing complications. Those studies were not randomized, however, so it is still unknown whether the technique itself is responsible for these benefits.
In this single-center randomized controlled trial, 110 adults with removable (resectable) cancer of the head of the pancreas will be assigned by chance, during the operation and after the surgeon has confirmed that the tumor can be removed, to pancreaticoduodenectomy with total mesopancreas excision or to standard pancreaticoduodenectomy. Patients, and the doctors who examine the removed tissue and the follow-up scans, will not be told which operation was performed. The main question is whether total mesopancreas excision increases the proportion of patients in whom no cancer cells are found within 1 mm of any cut edge (an R0 resection). The trial will also compare complications, diarrhea, recovery, the number of lymph nodes removed, the chance and pattern of cancer recurrence, survival and quality of life over 2 years of follow-up.
A vizsgálat 2 csoportja
- Pancreaticoduodenectomy With Total Mesopancreas ExcisionA vizsgált kezelés
Open pancreaticoduodenectomy using an artery-first approach with en bloc total mesopancreas excision: periadventitial dissection of the right hemicircumference (about 180 degrees) of the superior mesenteric artery from its aortic origin to the first jejunal artery, ligation of the inferior pancreaticoduodenal artery at its origin, and removal of the retropancreatic fat, lymphatic and neural tissue (including the right-sided superior mesenteric artery nerve plexus) down to the inferior vena cava, left renal vein and aorta, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the control arm.
- Standard PancreaticoduodenectomyMár használt kezelés, összehasonlításként
Open pancreaticoduodenectomy using the conventional vein-first approach, with division of the uncinate process from the superior mesenteric vein and the right side of the superior mesenteric artery close to the pancreas, without periadventitial dissection of the artery or resection of its nerve plexus, plus ISGPS standard lymphadenectomy. Reconstruction and perioperative care are identical to the experimental arm.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Mesopancreas Excision Versus Standard Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Ductal Adenocarcinoma: A Single-Center Randomized Controlled Trial
- Kérdések a feltételekről
- Forrás: NCT07946380: ki vehet részt
- A regiszteradat frissítve
- 2026. november 18.